Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
|ClinicalTrials.gov Identifier: NCT00941928|
Recruitment Status : Terminated (Slow accrual)
First Posted : July 20, 2009
Results First Posted : August 28, 2013
Last Update Posted : May 22, 2014
The goal of this clinical research study is to learn if transferring the donor's NK cells, in combination with an antibody called epratuzumab and low-dose interleukin (IL-2), into your body can be done safely. Researchers want to find out if the infused NK cells will survive after the infusion and if the NK cell infusion helps to destroy cancer cells in the recipient's body and possibly to help control the disease.
· Evaluate the feasibility of collecting an adequate number of natural killer (NK) cells from a donor and evaluate the safety of a haploidentical donor-derived NK cell infusion, Epratuzumab, and low-dose interleukin-2 (IL-2).
- Quantification and persistence of the infused donor NK cell in vivo;
- Quantification and persistence of cytokine levels;
- Assessment of NK cell immunophenotype and function;
- Correlate above with anti-tumor effect.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia Pediatric Cancer||Drug: Epratuzumab Drug: Fludarabine Drug: Cyclophosphamide Drug: Mesna Procedure: Infusion of NK cells Drug: Interleukin-2||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Adoptive Transfer of Haploidentical NK Cells in Combination With Epratuzumab for the Treatment of Relapsed Acute Lymphoblastic Leukemia|
|Study Start Date :||July 2009|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||May 2012|
Experimental: Haploidentical NK cells + Epratuzumab
Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
360 mg/m^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.Drug: Fludarabine
25 mg/m^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
Other Names:Drug: Cyclophosphamide
60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
Other Names:Drug: Mesna
12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
Other Name: MesnexProcedure: Infusion of NK cells
Transplant of Haploidentical NK cells by vein on Day 0.
Other Names:Drug: Interleukin-2
Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
- Time to Progression (TTP) [ Time Frame: 1 Year ]TTP calculated as average time, in months, from baseline to participants disease progression or death, monitored for a minimum of 1 year
- Overall Survival (OS) [ Time Frame: Minimum of 1 year, or until disease progression or death ]Number of surviving participants without disease progression or death for any reason at one year post treatment.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00941928
|United States, Texas|
|UT MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Study Chair:||Anna Franklin, MD||UT MD Anderson Cancer Center|